PUBLICATION Mammalian Cell Designers’ Laboratory

MISSION

Our mission is to engineer next-generation mammalian cell factories
for the production of complex biotherapeutics.
By integrating synthetic biology, genome engineering, and autonomous experimentation,
we aim to transform cell line development from empirical optimization into a predictive engineering discipline.

Journal Articles

Genome-wide CRISPR/Cas9 screening unveils a novel target ATF7IP–SETDB1 complex for enhancing difficult-to-express protein production
Author
Su Hyun Kim*, Jong-Ho Park, Sungwook Shin, Seunghyeon Shin, Dahyun Chun, Yeon-Gu Kim, Jiseon Yoo, Weon-Kyoo You, Jae Seong Lee‡, Gyun Min Lee‡
Journal
ACS Synthetic Biology
Vol
13(2)
Page
634-647
Year
2024

With the emerging novel biotherapeutics that are typically difficult-to-express (DTE), improvement is required for high-yield production. To identify novel targets that can enhance DTE protein production, we performed genome-wide fluorescence-activated cell sorting (FACS)-based clustered regularly interspaced short palindromic repeats (CRISPR) knockout screening in bispecific antibody (bsAb)-producing Chinese hamster ovary (CHO) cells. The screen identified the two highest-scoring genes, Atf7ip and Setdb1, which are the binding partners for H3K9me3-mediated transcriptional repression. The ATF7IP-SETDB1 complex knockout in bsAb-producing CHO cells suppressed cell growth but enhanced productivity by up to 2.7-fold. Decreased H3K9me3 levels and an increased transcriptional expression level of the transgene were also observed. Furthermore, perturbation of the ATF7IP-SETDB1 complex in monoclonal antibody (mAb)-producing CHO cells led to substantial improvements in mAb production, increasing the productivity by up to 3.9-fold without affecting the product quality. Taken together, the genome-wide FACS-based CRISPR screen identified promising targets associated with histone methylation, whose perturbation enhanced the productivity by unlocking the transgene expression.